Opus Genetics (NASDAQ:IRD) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research cut shares of Opus Genetics (NASDAQ:IRD) from a hold rating to a strong sell rating in a research note published on Tuesday,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. Wall Street Zen raised shares of Opus Genetics from a “sell” rating to a “hold” rating in a research report on Sunday, March 1st. Oppenheimer began coverage on shares of Opus Genetics in a research report on Monday, March 16th. They set an “outperform” rating and a $10.00 target price on the stock. Citizens Jmp lowered their target price on shares of Opus Genetics from $12.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Wednesday. Cantor Fitzgerald started coverage on Opus Genetics in a research report on Monday, March 30th. They issued an “overweight” rating and a $15.00 price target on the stock. Finally, Lifesci Capital raised Opus Genetics to a “strong-buy” rating in a research report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.20.

Opus Genetics Trading Down 2.9%

Shares of NASDAQ:IRD opened at $5.03 on Tuesday. Opus Genetics has a 1 year low of $0.90 and a 1 year high of $5.81. The business has a fifty day simple moving average of $4.97 and a 200 day simple moving average of $3.31. The firm has a market cap of $359.15 million, a price-to-earnings ratio of -3.78 and a beta of 0.62.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.59). Opus Genetics had a negative return on equity of 709.20% and a negative net margin of 892.36%.The firm had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $2.93 million. On average, sell-side analysts forecast that Opus Genetics will post -0.57 EPS for the current year.

Insider Buying and Selling at Opus Genetics

In other Opus Genetics news, President Benjamin R. Yerxa sold 7,470 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $5.24, for a total transaction of $39,142.80. Following the completion of the transaction, the president owned 711,535 shares in the company, valued at $3,728,443.40. This trade represents a 1.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 7,842 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $5.18, for a total transaction of $40,621.56. Following the transaction, the chief financial officer owned 592,158 shares of the company’s stock, valued at approximately $3,067,378.44. This represents a 1.31% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 73,395 shares of company stock worth $382,278 in the last three months. 11.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IRD. Comerica Bank bought a new position in shares of Opus Genetics in the first quarter valued at approximately $29,000. Royal Bank of Canada bought a new position in shares of Opus Genetics in the first quarter valued at approximately $299,000. Nantahala Capital Management LLC raised its stake in shares of Opus Genetics by 6.0% in the second quarter. Nantahala Capital Management LLC now owns 3,345,923 shares of the company’s stock valued at $3,152,000 after acquiring an additional 188,028 shares during the last quarter. Mink Brook Asset Management LLC raised its stake in shares of Opus Genetics by 47.8% in the second quarter. Mink Brook Asset Management LLC now owns 1,197,616 shares of the company’s stock valued at $1,128,000 after acquiring an additional 387,536 shares during the last quarter. Finally, Opaleye Management Inc. raised its stake in shares of Opus Genetics by 3.8% in the second quarter. Opaleye Management Inc. now owns 1,220,000 shares of the company’s stock valued at $1,149,000 after acquiring an additional 45,000 shares during the last quarter. Institutional investors own 14.97% of the company’s stock.

Opus Genetics News Roundup

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Opus Genetics announced it will present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, which could help keep investor attention on the stock and provide a near-term catalyst. Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
• Positive Sentiment: The company said its cash runway into 2029 should fund several clinical milestones, including data readouts and program advancement, which supports the long-term investment case. Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
• Neutral Sentiment: Analysts at Citizens JMP lowered their price target to $11 from $12 but kept a “market outperform” rating, suggesting continued optimism despite a modest valuation reset.
• Neutral Sentiment: Lifesci Capital cut earnings estimates for Q2, Q3, Q4 and FY2026, but maintained a “Strong-Buy” rating, indicating the revisions were more about near-term losses than a change in the longer-term outlook.
• Negative Sentiment: Opus Genetics reported a wider-than-expected first-quarter loss of $0.75 per share versus expectations for a $0.16 loss, which is the clearest reason the stock is being sold today. Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Revenue came in at just $2.16 million, and the company continues to post large losses and negative margins, reinforcing concerns about profitability in the near term.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.